ZFIN ID: ZDB-FISH-150901-25885
Fish name: b1212Tg
Genotype: b1212Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by b1212Tg
Human Disease Conditions Citations
glucocorticoid-induced osteoporosis chemical treatment by environment: dexamethasone Zhong et al., 2021
GENE EXPRESSION
Gene expression in b1212Tg
RNA expression No data available
PHENOTYPE
Phenotype in b1212Tg
Phenotype Conditions Figures
caudal fin principal ray bone callus EGFP expression increased amount, abnormal compression injury: caudal fin Fig 2 with image from McGowan et al., 2021
cranium bone mineralization disrupted, abnormal chemical treatment by environment: dexamethasone Fig. 6 from Zhong et al., 2021
cranium bone mineralization process quality, ameliorated chemical treatment by environment: quercetin, chemical treatment by environment: dexamethasone Fig. 6 from Zhong et al., 2021
cranium osteoblast EGFP expression amount, ameliorated chemical treatment by environment: dexamethasone, chemical treatment by environment: calcitriol Fig. 7 from Luo et al., 2016
cranium osteoblast EGFP expression amount, ameliorated chemical treatment by environment: salvianolic acid B, chemical treatment by environment: dexamethasone Fig. 7 from Luo et al., 2016
cranium osteoblast EGFP expression decreased amount, abnormal chemical treatment by environment: dexamethasone Fig. 2Fig. 7 from Luo et al., 2016
cranium osteoblast EGFP expression decreased distribution, abnormal chemical treatment by environment: dexamethasone Fig. 2Fig. 7 from Luo et al., 2016
cranium osteoblast EGFP expression decreased distribution, abnormal chemical treatment by environment: dexamethasone Fig. 6 from Zhong et al., 2021
cranium osteoblast EGFP expression increased amount, abnormal chemical treatment by environment: salvianolic acid B Fig. 4 from Luo et al., 2016
cranium osteoblast EGFP expression increased distribution, abnormal chemical treatment by environment: salvianolic acid B Fig. 4 from Luo et al., 2016
cranium osteoblast EGFP expression position, ameliorated chemical treatment by environment: quercetin, chemical treatment by environment: dexamethasone Fig. 6 from Zhong et al., 2021
cranium osteoblast differentiation decreased occurrence, abnormal chemical treatment by environment: dexamethasone Fig. 2Fig. 7 from Luo et al., 2016
cranium osteoblast differentiation increased occurrence, abnormal chemical treatment by environment: salvianolic acid B Fig. 4 from Luo et al., 2016
cranium osteoblast differentiation occurrence, ameliorated chemical treatment by environment: salvianolic acid B, chemical treatment by environment: dexamethasone Fig. 7 from Luo et al., 2016
cranium osteoblast differentiation occurrence, ameliorated chemical treatment by environment: dexamethasone, chemical treatment by environment: calcitriol Fig. 7 from Luo et al., 2016
opercle postero-ventral margin decreased length, abnormal chemical treatment: Cyclopamine Fig. 8 with image from Huycke et al., 2012

CITATIONS  (18)